{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.4.4 Physical and Ophthalmic Examinations, Height, and Weight', 'A physical examination, including complete undilated ophthalmic examination, will be', 'performed at Baseline (Day 1) and thereafter at Weeks 1, 6, 12, 18, and 24 (or PW) at EOT', 'during the Treatment Period and Month 12 (or PWEOS) of the Follow-Up Period.', 'Physical exam will include assessment of presence or absence of pretibial myxedema on Day 1', 'and EOT Week 24 (or PW) of the Treatment Period and Month 12/PWEOS of the Follow-Up', 'Period. If present, measurements of instep and calf will be taken.', 'Weight will be measured at Baseline and every 12 weeks throughout the study (Weeks 12 and 24', '[or PWI EOT during the Treatment Period and Months 9 and 12 [or PWEOS] of the Follow-Up', 'Period). The dose on Day 1 may be based on the weight determined at the most recent clinic', 'visit, provided the most recent visit was within the prior 3 weeks. The doses on Week 3 through', 'Week 912 will be based on the weight determined on Day 1. The weight used in the Week 12', 'dose calculation can be the weight determined on Day 1 or the weight obtained at Week 12.', 'and the doses on Weeks 18 through 21 may be adjusted based on the weight obtained at Week', '12, as appropriate. The weight obtained at Week 12 can be used to adjust the dose beginning', 'at Week 12 or Week 15 through Week 21, as appropriate.', '9.5.4.5 ECGs', '12-lead ECGs will be performed at Baseline, Weeks 3, 6, 12, and 24 (or PW) EOT of the', 'Treatment Period, and Month 12 (or PWEOS) of the Follow-Up Period. At infusion visits, the', 'ECG will be performed prior to the infusion. The results will be recorded as normal or abnormal', 'on the eCRF and all abnormal results will be evaluated as clinically (CS) or not clinically', 'significant (NCS) by the Investigator. A copy of the ECG tracing will remain with the source', 'documents.', '9.5.4.7 Immunogenicity Testing', 'Blood samples will be collected in a 5 mL SST collection tube for immunogenicity testing (ADA', 'and possibly Neutralizing Antibodies [NAb]) from all subjects prior to dosing on Day 1, prior to', 'dosing on Weeks 3 and 9, and at Week 24 (or EOT) of the Treatment Period, and Months 9 and', '12 (or PWEOS) of the Follow-Up Period. Samples will be collected, processed, and stored at', '> -70\u00b0C at the site until shipment to the central laboratory', 'will store the samples at >-70\u00b0C until shipment to', 'for immunogenicity testing.', 'If a subject tests positive for ADA after confirmatory and reactive titer testing, the sample will', 'then be tested for NAb. If the subject tests positive for NAb, he/she will be followed until levels', \"either revert to Baseline or the subject's value decreases or remains stable. Any subject with a\", 'positive NAb test at Month 12 (or PWEOS) of the Follow-Up Period will continue to be', \"followed until the subject's value decreases or remains stable.\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 23 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.5', 'Appropriateness of Measurements', 'The measurements used in this study for the primary and secondary endpoints (proptosis, CAS,', 'diplopia and GO-QoL questionnaire) are established endpoints that have been shown to correlate', 'significantly with TED.', '9.5.6.1', 'Day 1/Baseline', 'Collect predose blood samples for immunogenicity and PK testing.', 'Perform predose Baseline efficacy assessments (CAS, Clinical Measures of Severity', 'including proptosis, diplopia and motility restriction proptosis, CAS, Clinical', 'Measures of Severity including motility restriction).', 'Contact IWRS to rRegister enrollment in EDC, obtain study medication vial assignment;', 'and to determine the volume of study drug to be administered.', 'Collect blood samples for PK analyses at the end of the infusion.', '9.5.6.2', 'Week 1', 'Collect blood sample for PK analyses. Record date/time of sample collection.', '9.5.6.3 Week 3', 'Collect predose blood samples for immunogenicity and PK testing.', 'Contact IWRS to oObtain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', 'Collect blood samples for PK analyses at the end of the infusion.', '9.5.6.4', 'Week 4', 'Collect blood sample for PK analyses. Record date/time of sample collection.', '9.5.6.5 Week 6', 'Perform predose efficacy assessments (CAS, Clinical Measures of Severity including', 'proptosis, diplopia and motility restriction).', 'Contact IWRS to obbain study medication vial assignment and to determine volume of', 'study drug to be administered from EDC.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 24 of 118']\n\n###\n\n", "completion": "END"}